Skip to main
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is poised for strong growth with the successful launch of Zelsuvmi, a new at-home treatment for molluscum contagiosum. This product is expected to generate significant revenue for the company and gain market share through pediatricians. With additional approved products and a promising pipeline, Pelthos has the potential to gain a larger market share and provide a strong return on investment. However, investors should closely monitor commercial execution and partnerships, which could pose potential risks.

Bears say

Pelthos Therapeutics is showing strong performance, with accelerating momentum and positive feedback on its Zelsuvmi product. The company's differentiated nitric oxide platform and high barriers to entry provide a competitive advantage, especially in the ocular pain market. However, there are potential risks to consider, such as regulatory and financing risks, and potential competition from other products targeting similar indications. Further success in clinical trials and securing reimbursement will be key factors in the company's future success.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.